Endometriosis Trial, Recruiting (NCT07173127)

Endometriosis Trial, Recruiting NCT07173127 Sponsor: University Hospital, Geneva Condition: Endometriosis

Printed from Voxsanity (voxsanity.com.au) — NCT07173127 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Endometriosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who are seen at the DFEA department of the HUG (a hospital clinic) and have been prescribed the medication Ryeqo® by their doctor for an approved medical condition
Women aged 18 years or older

Who may not be able to join:

Women who are not able to speak and/or read French
Women who have used certain hormonal medications in the past 3 months, including combined hormone pills (taken by mouth, worn as a patch, or used as a vaginal ring), estrogen tablets taken by mouth, or specific injectable or oral hormonal treatments (DMPA or nomegestrol acetate)
Women who have not agreed to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Patrick Petignat, Prof, University Hospital, Geneva

Phone: +41 79 55 35 385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07173127

Sponsor: University Hospital, Geneva

Phase: Not Applicable

Status: Recruiting

Condition: Endometriosis

Trial contact: +41 79 55 35 385

More information: https://clinicaltrials.gov/study/NCT07173127

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who are seen at the DFEA department of the HUG (a hospital clinic) and have been prescribed the medication Ryeqo® by their doctor for an approved medical condition
Women aged 18 years or older

Who may not be able to join:

Women who are not able to speak and/or read French
Women who have used certain hormonal medications in the past 3 months, including combined hormone pills (taken by mouth, worn as a patch, or used as a vaginal ring), estrogen tablets taken by mouth, or specific injectable or oral hormonal treatments (DMPA or nomegestrol acetate)
Women who have not agreed to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Geneva

Registry

ClinicalTrials.gov

Start date

30 September 2025

Est. completion

30 December 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Change from baseline in the mean value of normalized activated protein C resistance (nAPCsr) at 3 months of treatment with Ryeqo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov